Literature DB >> 34904187

Intratumoral and Peritumoral Analysis of Mammography, Tomosynthesis, and Multiparametric MRI for Predicting Ki-67 Level in Breast Cancer: a Radiomics-Based Study.

Tao Jiang1, Jiangdian Song2, Xiaoyu Wang3, Shuxian Niu1, Nannan Zhao3, Yue Dong3, Xingling Wang3, Yahong Luo3, Xiran Jiang4.   

Abstract

PURPOSE: To noninvasively evaluate the use of intratumoral and peritumoral regions from full-field digital mammography (DM), digital breast tomosynthesis (DBT), dynamic contrast-enhanced (DCE), and diffusion-weighted (DW) magnetic resonance imaging (MRI) images separately and combined to predict the Ki-67 level based on radiomics. PROCEDURES: A total of 209 patients with pathologically confirmed breast cancer were consecutively enrolled from September 2017 to March 2021, who underwent DM, DBT, DCE-MRI, and DW MRI scans. Radiomics features were calculated from intratumoral and peritumoral regions in each modality and selected with the least absolute shrinkage and selection operator (LASSO) regression. Radiomics signatures (RSs) were built based on intratumoral, peritumoral, and combined intra- and peritumoral regions. The prediction performance of the RSs was evaluated using the area under the receiver operating characteristic curve (AUC), specificity, and sensitivity as comparison metrics. A nomogram was constructed by integrating the multi-model RS and important clinical predictors and assessed by calibration and decision curve analysis.
RESULTS: The combined intra- and peritumoral RSs improved the AUC compared with intra- or peritumoral RSs in each modality. The DCE plus DW MRI yielded higher AUC and specificity but lower sensitivity compared with the DM plus DBT. The nomogram incorporating the multi-model RS, age, and lymph node metastasis status achieved the best prediction performance in the training (AUC, nomogram vs. fusion RS vs. clinical model, 0.922 vs. 0.917 vs. 0.672) and validation (AUCs, nomogram vs. fusion RS vs. clinical model, 0.866 vs. 0.838 vs. 0.661) cohorts. DCA analysis confirmed the potential clinical utility of the nomogram.
CONCLUSIONS: Peritumoral regions can provide complementary information to intratumoral regions in mammography and MRI for the prediction of Ki-67 levels. The MRI performed better than mammography in terms of AUC and specificity but weaker in sensitivity. The nomogram has a predictive advantage over each modality and could be a potential tool for predicting Ki-67 levels in breast cancer.
© 2021. World Molecular Imaging Society.

Entities:  

Keywords:  Breast; Ki-67 level; MRI; Mammography; Radiomics

Mesh:

Substances:

Year:  2021        PMID: 34904187     DOI: 10.1007/s11307-021-01695-w

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.484


  2 in total

1.  Breast cancer Ki67 expression prediction by DCE-MRI radiomics features.

Authors:  W Ma; Y Ji; L Qi; X Guo; X Jian; P Liu
Journal:  Clin Radiol       Date:  2018-06-30       Impact factor: 2.350

2.  Correlation between DCE-MRI radiomics features and Ki-67 expression in invasive breast cancer.

Authors:  Ma-Wen Juan; Ji Yu; Guo-Xin Peng; Liu-Jun Jun; Sun-Peng Feng; Liu-Pei Fang
Journal:  Oncol Lett       Date:  2018-08-06       Impact factor: 2.967

  2 in total
  2 in total

1.  Development of an ultrasound-based radiomics nomogram to preoperatively predict Ki-67 expression level in patients with breast cancer.

Authors:  Jinjin Liu; Xuchao Wang; Mengshang Hu; Yan Zheng; Lin Zhu; Wei Wang; Jisu Hu; Zhiyong Zhou; Yakang Dai; Fenglin Dong
Journal:  Front Oncol       Date:  2022-08-15       Impact factor: 5.738

2.  Radiomic and Artificial Intelligence Analysis with Textural Metrics Extracted by Contrast-Enhanced Mammography and Dynamic Contrast Magnetic Resonance Imaging to Detect Breast Malignant Lesions.

Authors:  Roberta Fusco; Elio Di Bernardo; Adele Piccirillo; Maria Rosaria Rubulotta; Teresa Petrosino; Maria Luisa Barretta; Mauro Mattace Raso; Paolo Vallone; Concetta Raiano; Raimondo Di Giacomo; Claudio Siani; Franca Avino; Giosuè Scognamiglio; Maurizio Di Bonito; Vincenza Granata; Antonella Petrillo
Journal:  Curr Oncol       Date:  2022-03-13       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.